Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 4;12(11):e063856.
doi: 10.1136/bmjopen-2022-063856.

Investigating the association between IL-6 antagonist therapy and blood coagulation in critically ill patients with COVID-19: a protocol for a prospective, observational, multicentre study

Emőke Henrietta Kovács  1   2   3 , Máté Rottler  4 , Fanni Dembrovszky  1   5 , Klementina Ocskay  1   5 , László Szabó  1   5 , Péter Hegyi  1   5   6 , Zsolt Molnár  1   3   7 , Krisztián Tánczos  8   9
Affiliations

Investigating the association between IL-6 antagonist therapy and blood coagulation in critically ill patients with COVID-19: a protocol for a prospective, observational, multicentre study

Emőke Henrietta Kovács et al. BMJ Open. .

Abstract

Introduction: Hypercoagulation is one the main features of COVID-19. It is induced by the hyperinflammatory response that shifts the balance of haemostasis towards pro-coagulation. Interleukin-6 (IL-6) antagonist therapy has been recommended in certain subgroups of critically ill patients with COVID-19 to modulate inflammatory response. The interaction between immune response and haemostasis is well recognised. Therefore, our objective is to evaluate whether the modulation of the inflammatory response by IL-6 antagonist inflicts any changes in whole blood coagulation as assessed by viscoelastic methods in critically ill patients with COVID-19.

Methods and analysis: In this prospective observational study, we are going to collect data on inflammatory parameters and blood coagulation using the ClotPro® device. The primary outcome is the change of the fibrinolytic system measured by the Lysis Time and Lysis onset time before and after immunomodulation therapy. Data will be collected before the IL-6 antagonist administration at baseline (T0) then after 24, 48 hours, then on day 5 and 7 (T1-4, respectively). Secondary outcomes include changes in other parameters related to inflammation, blood coagulation and biomarkers of endothelial injury.

Ethics and dissemination: Ethical approval was given by the Medical Research Council of Hungary (1405-3/2022/EÜG). All participants provided written consent. The results of the study will be disseminated through peer-reviewed journals.

Trial registration number: NCT05218369; Clinicaltrials.gov.

Keywords: Adult intensive & critical care; Bleeding disorders & coagulopathies; COVID-19.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8:e46–7. 10.1016/S2213-2600(20)30216-2 - DOI - PMC - PubMed
    1. Llitjos J-F, Leclerc M, Chochois C, et al. . High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020;18:1743–6. 10.1111/jth.14869 - DOI - PMC - PubMed
    1. Levy JH, Iba T, Olson LB, et al. . COVID-19: thrombosis, thromboinflammation, and anticoagulation considerations. Int J Lab Hematol 2021;43 Suppl 1:29–35. 10.1111/ijlh.13500 - DOI - PMC - PubMed
    1. Cuker A, Tseng EK, Nieuwlaat R, et al. . American society of hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv 2022;6:4915–23. 10.1182/bloodadvances.2022007561 - DOI - PMC - PubMed
    1. National Iinstitute of Health COVID-19 Treatment Guidelines . Antithrombotic therapy in patients with COVID-19, 2022. Available: https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-... [Accessed 23 Aug 2022].

Publication types

Associated data